PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

Transine Therapeutics raises £13.7m in seed round led by Eipdarex Capital

Transine Therapeutics (Transine), a biotechnology company developing a novel class of therapeutic RNAs based on its SINEUP platform technology, has raised £4.6 million in an additional seed funding round led by new investor Epidarex Capital.

Existing investor the Dementia Discovery Fund (DDF) also participated in the round.
 
The new funds will enable Transine to further exploit its unique SINEUP platform and accelerate the development of its product portfolio, building on recent advances with its lead programmes in Central Nervous System and Ophthalmology indications with key in vivo data expected this year.

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured